Every 10-Q that AbCellera Biologics Inc. (ABCL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABCL filings page.
AbCellera Biologics is a clinical-stage biotechnology company focused on antibody medicines. For the quarter ended June 30, 2026, it generated $4.1 million in revenue and recorded a net loss of $55.4 million, or $0.18 per share, reflecting sharply lower licensing and royalty revenue and higher research and development spending.
Despite ongoing losses, liquidity remains strong with $540.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, and operating cash outflow improved to $7.6 million for the first half of 2026. The company also has access to an estimated $110.0 million of future government funding.
Strategically, AbCellera signed a major collaboration with Jazz Pharmaceuticals, receiving a $56.0 million non-refundable upfront payment and eligibility for substantial milestones and royalties on T‑cell engaging antibodies. A separate agreement with Vertex Pharmaceuticals added $28.0 million upfront and additional potential milestone and royalty streams, while internal programs ABCL635 and ABCL575 advanced in clinical development.
AbCellera Biologics reported a net loss of $43.2M for the quarter ended March 31, 2026, slightly improved from $45.6M a year earlier. Revenue nearly doubled to $8.3M, driven by higher research fees, but remains modest relative to expenses.
Research and development spending rose to $46.7M as the company advanced internal programs ABCL635, ABCL575 and ABCL688. Sales, general and administrative costs fell to $12.3M, reflecting lower legal and overhead spending. AbCellera ended the quarter with $504.7M in cash, cash equivalents and marketable securities, providing a sizable runway despite increased cash use.
The company highlighted progress in its transition toward an internal clinical pipeline, including positive interim Phase 1 data for ABCL635 and ongoing Phase 2 enrollment, while continuing to rely on government contributions and a large securities portfolio to fund operations.
AbCellera Biologics (ABCL) reported a wider quarterly loss while progressing its first proprietary programs into the clinic. For the quarter ended September 30, 2025, revenue was $8.955 million, driven mainly by research fees. Net loss was $57.119 million, or $0.19 per share. For the first nine months of 2025, revenue reached $30.275 million and net loss totaled $137.467 million.
Total cash, cash equivalents, and marketable securities were $495.672 million as of September 30, 2025, compared with $625.614 million at December 31, 2024. Operating expenses fell year over year due to the absence of 2024 impairment charges, though research and development rose to $55.028 million in the quarter as the company advanced internal programs and began clinical activities. AbCellera initiated Phase 1 trials in the second half of 2025 for ABCL635 (vasomotor symptoms) and ABCL575 (OX40L antibody for inflammation) after receiving Health Canada No Objection Letters in May. The company reported 103 partner-initiated programs with downstream participation and 18 molecules in the clinic. Common shares outstanding were 299,335,048 as of November 3, 2025.